Cargando…
Personalized medicine with biologics for severe type 2 asthma: current status and future prospects
Asthma affects more than 300 million people worldwide and poses a large socioeconomic burden, particularly in the 5% to 10% of severe asthmatics. So far, each entry of new biologics in clinical trials has led to high expectations for treating all severe asthma forms, but the outcome has only been su...
Autores principales: | Godar, Marie, Blanchetot, Christophe, de Haard, Hans, Lambrecht, Bart N., Brusselle, Guy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800381/ https://www.ncbi.nlm.nih.gov/pubmed/29035619 http://dx.doi.org/10.1080/19420862.2017.1392425 |
Ejemplares similares
-
Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy
por: Godar, Marie, et al.
Publicado: (2016) -
Personalized Medicine in Asthma: Current Approach and Future Perspectives
por: Nolasco, Santi, et al.
Publicado: (2023) -
Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease
por: Yamamoto, Yuichi, et al.
Publicado: (2022) -
Current status and future directions of personalized medicine
por: Bryce, Alan Haruo, et al.
Publicado: (2013) -
The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
por: Derom, Eric, et al.
Publicado: (2019)